发送询价
产品名称：Mouse/Rat FGF-21 ELISA Kit
产地：捷克
规格：96T
货号：RD291108200R
1. INTENDED USE
The RD291108200R Mouse and Rat FGF-21 ELISA is a sandwich enzyme immunoassay for
the quantitative measurement of mouse and/or rat FGF-21 (fibroblast growth factor-21).
2.Features
· It is intended for research use only
· The total assay time is less than 3.5 hours
· The kit measures FGF-21 in serum
· Assay format is 96 wells
· Quality Controls are mouse and rat serum based. No human sera are used
· Standard is mouse recombinant protein based
· Components of the kit are provided ready to use, concentrated or lyophilized
3. INTRODUCTION
The fibroblast growth factor family (FGFs) are a family of more than 20 small (17-26 kDa)
secreted peptides. The initial characterisation of these proteins focused on their ability to
stimulate fibroblast proliferation through FGF receptors ( FGFRs). Members of FGFs family play important roles in defining and regulating the development and function of endocrine tissues as well as modulating various metabolic processes.
A recently described member of FGFs family, FGF-21, also called Fibroblast growth factor 21
precursor and UNQ3115/PRO10196, has been characterised as a potent metabolic regulator.
FGF-21 is preferentially expressed in liver and regulates glucose uptake in fat cells. Moreover,
therapeutic administration of FGF-21 decreased plasma glucose levels and triglycerides to
near normal levels in multiple mouse models of type 2 diabetes. Short-term treatment of
normal or db/db mice with FGF-21 lowered plasma levels of insulin and improved glucose
clearance compared with vehicle after oral glucose tolerance testing. Constant infusion of
FGF-21 for 8 weeks in db/db mice nearly normalized fed blood glucose levels and increased
plasma insulin levels. When administrated daily for 6 weeks to diabetic rhesus monkeys,
FGF-21 caused dramatic decline in fasting plasma glucose, fructosamine, triglicerides, insulin,and glucagon. FGF-21 administration also led to significant improvements in lipoprotein
profiles, including lowering of low-density lipoprotein cholesterol and raising of high-density
lipoprotein cholesterol as well as beneficial changes in the circulating levels of several
cardiovascular risk factors.
FGF-21, when overexpressed, protected animals from diet-induced obesity. These results
define a functional role for FGF-21 in vivo and provide evidence that FGF-21 can lower glucose and triglyceride levels in diabetic animals.
In contrast to several members of the FGF family which may induce therapeutically undesirable in vivo proliferation of various cell types, a recent study demonstrated that FGF-21 did not induce mitogenicity, hypoglycemia or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, FGF-21 appears to have
considerable potential for the treatment of diabetes mellitus.
网址：http://www.craymeibio.com/
产地：捷克
规格：96T
货号：RD291108200R
1. INTENDED USE
The RD291108200R Mouse and Rat FGF-21 ELISA is a sandwich enzyme immunoassay for
the quantitative measurement of mouse and/or rat FGF-21 (fibroblast growth factor-21).
2.Features
· It is intended for research use only
· The total assay time is less than 3.5 hours
· The kit measures FGF-21 in serum
· Assay format is 96 wells
· Quality Controls are mouse and rat serum based. No human sera are used
· Standard is mouse recombinant protein based
· Components of the kit are provided ready to use, concentrated or lyophilized
3. INTRODUCTION
The fibroblast growth factor family (FGFs) are a family of more than 20 small (17-26 kDa)
secreted peptides. The initial characterisation of these proteins focused on their ability to
stimulate fibroblast proliferation through FGF receptors ( FGFRs). Members of FGFs family play important roles in defining and regulating the development and function of endocrine tissues as well as modulating various metabolic processes.
A recently described member of FGFs family, FGF-21, also called Fibroblast growth factor 21
precursor and UNQ3115/PRO10196, has been characterised as a potent metabolic regulator.
FGF-21 is preferentially expressed in liver and regulates glucose uptake in fat cells. Moreover,
therapeutic administration of FGF-21 decreased plasma glucose levels and triglycerides to
near normal levels in multiple mouse models of type 2 diabetes. Short-term treatment of
normal or db/db mice with FGF-21 lowered plasma levels of insulin and improved glucose
clearance compared with vehicle after oral glucose tolerance testing. Constant infusion of
FGF-21 for 8 weeks in db/db mice nearly normalized fed blood glucose levels and increased
plasma insulin levels. When administrated daily for 6 weeks to diabetic rhesus monkeys,
FGF-21 caused dramatic decline in fasting plasma glucose, fructosamine, triglicerides, insulin,and glucagon. FGF-21 administration also led to significant improvements in lipoprotein
profiles, including lowering of low-density lipoprotein cholesterol and raising of high-density
lipoprotein cholesterol as well as beneficial changes in the circulating levels of several
cardiovascular risk factors.
FGF-21, when overexpressed, protected animals from diet-induced obesity. These results
define a functional role for FGF-21 in vivo and provide evidence that FGF-21 can lower glucose and triglyceride levels in diabetic animals.
In contrast to several members of the FGF family which may induce therapeutically undesirable in vivo proliferation of various cell types, a recent study demonstrated that FGF-21 did not induce mitogenicity, hypoglycemia or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, FGF-21 appears to have
considerable potential for the treatment of diabetes mellitus.
网址：http://www.craymeibio.com/